Nantkwest, Inc. (NK): Soon-shiong Family Founda Chan , CEO of Nantkwest, Inc. purchased 5,618,326 shares on Jul 7, 2016. The Insider buying transaction was reported by the company on Jul 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.00 per share for a total value of $0.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 11, 2015, Angela Wilson (CFO) purchased 3,265 shares at $15.31 per share price.On Aug 25, 2015, 13 Ventures, Llc Mp (CEO) purchased 450,000 shares at $23.00 per share price.Also, On Aug 25, 2015, Steve Gorlin (director) sold 450,000 shares at $23.00 per share price.
Nantkwest Inc: On Friday, Jul 8, 2016 heightened volatility was witnessed in Nantkwest Inc which led to swings in the share price. The shares opened for trading at $6.64 and hit $6.85 on the upside , eventually ending the session at $6.72, with a gain of 1.51% or 0.1 points. The heightened volatility saw the trading volume jump to 3,01,977 shares. The 52-week high of the share price is $38.48 and the company has a market cap of $551 M . The 52-week low of the share price is at $5.43.
Company has been under the radar of several Street Analysts.Nantkwest Inc is Initiated by Raymond James to Mkt Perform. The Rating was issued on Jun 2, 2016.
NantKwest Inc. formerly Conkwest Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer infectious diseases and inflammatory diseases. The Company’s product candidates include aNK haNK and taNK. The Company’s aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers such as polyomavirus induced Merkel cell carcinoma human Papillomavirus (HPV) induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16 a receptor that allows direct binding of NK cells to antibodies. The Company’s taNK product candidate targets specific antigens on the surface of abnormal cells including CD33 EGFR HER2/neu PDL1 and PSMA.